Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (“SPKB”) (NASDAQ: SPKB/SPKBU/SPKBW), a publicly traded special purpose acquisition company (“SPAC”) sponsored by an affiliate of Silver Spike Capital (“Silver Spike”), announced Thursday that they have signed a definitive business combination agreement expected to make Eleusis a public company. Upon the close of the transaction, the combined company will be operated through Eleusis Inc., a new holding company, and will apply to have its common stock listed on Nasdaq under the symbol “ELEU.”
Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, announces that, further to its press release dated December 23, 2021, it has closed its acquisition (the “Acquisition”) of Arizona-based Foundations for Change, Inc. (“Foundations”), a mental health practice specialized in ketamine-assisted psychotherapy. “We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine for treatment of Lennox-Gastaut syndrome (LGS).
ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (“SCS”) (Nasdaq: DNAC), a special purpose acquisition company. Upon closing, the transaction will accelerate ProKidney’s mission to change the lives of tens of millions of CKD patients through a first-of-its-kind disease-modifying autologous cellular therapy.
Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems.
Covaris, Inc. (“Covaris” or “the Company”), a manufacturer of advanced tools enabling life science innovations, announced today that New Mountain Capital (“New Mountain”), a leading growth-oriented investment firm with over $35 billion in assets under management, has made a majority investment in the Company. Covaris’ tools are central to multiple sample analysis technologies, including sequencing and proteomics. In sequencing, Covaris technology is the gold standard for sample preparation, DNA extraction and shearing.
REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida (“Acquisition”). Revitalist had previously announced the Acquisition non-binding letter of intent on October 27, 2021. This Acquisition represents the ninth clinic for the Company and is expected to commence under the Revitalist brand by February 1, 2022.
DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the completion of its investment in Vets Plus, Inc and Noble Pharma, LLC (“Vets Plus “, “Noble”, or the “Company”). Vets Plus is a full-service developer and manufacturer of nutraceutical solutions for the companion animal and livestock markets. Noble is an FDA registered manufacturer of animal health pharmaceuticals. Since 1990, Vets Plus has been a trusted supplier developing uncommonly palatable products for a diverse set of customers.
Castle Creek Biosciences, Inc., a late-clinical stage cell and gene therapy company focused on developing and preparing to commercialize disease-modifying and potentially curative therapies for rare genetic diseases, today announced it has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases. The acquisition expands Castle Creek’s technology platform by adding in vivo capabilities to its existing ex vivo approach, and broadens Castle Creek’s development pipeline beyond skin and connective tissue disorders to rare liver diseases.
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of its acquisition of Lowell Therapeutics, Inc. (Lowell). “We are thrilled to finalize the acquisition of Lowell as we continue to execute on our strategy to expand our portfolio of innovative therapies for use in medically supervised settings with the addition of Niyad™, an investigational product that has received Breakthrough Designation status from the FDA,” said Vince Angotti, CEO of AcelRx Pharmaceuticals.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.